Lorlatinib for advanced ALK plus non-small cell lung cancer (NSCLC): Efficacy and safety data from IFCT-1803 LORLATU expanded access program (EAP) cohort

Affiliation auteursAffiliation ok
TitreLorlatinib for advanced ALK plus non-small cell lung cancer (NSCLC): Efficacy and safety data from IFCT-1803 LORLATU expanded access program (EAP) cohort
Type de publicationJournal Article
Year of Publication2020
AuteursBaldacci S., Besse B., Avrillon V., Mennecier B., Dubray-Longeras P., Mazieres J., Descourt R., Duruisseaux M., Quantin X., Doubre H., Monnet I., Moro-Sibilot D., Schneider S., Cousin S., Merle P., Otto J., Langlais A., Morin F., Westeel V., Girard N.
JournalANNALS OF ONCOLOGY
Volume31
PaginationS843
Date PublishedSEP
Type of ArticleMeeting Abstract
ISSN0923-7534
DOI10.1016/j.annonc.2020.08.1617